Articles tagged with Antibodies
Researchers at UCLA have identified how an antibody blocks prostate cancer growth by signaling cells to stop growing and die. The discovery could lead to a new treatment targeting prostate stem cell antigen, also found in bladder and pancreatic cancers.
A team of scientists at Sanford Burnham Prebys found that an antibody produced in reaction to a naturally-occurring sugar chain curbs intestinal inflammation induced in mice, reversing early symptoms and halting disease progression. The research holds promise for treating Crohn's disease and other inflammatory disorders.
Researchers have developed a faster method to create antibodies for disease research, enabling the study of proteins at a higher rate. The new technique uses synthetic peptide immunisation and binds specifically to proteins with a precise sequence, producing highly specific antibodies.
Researchers at Yale University have developed two ways to induce MS symptoms in mice, revealing a key distinction between disease-causing and non-disease antibodies. The study brings the team closer to pinpointing accurate diagnostic tools for individual MS patients.
The BEADS system detects toxin from environmental samples, then uses antibodies to purify and concentrate the pathogen or toxin for accurate detection. The system has been commercially licensed and can detect multiple pathogens simultaneously.
A study found a strong relationship between HCV infection and having an anti-HCV positive family member, with the highest incidence rate in children under 10 living in households with an anti-HCV positive parent. Parenteral exposures increased the risk of HCV, particularly in men married to an HCV positive woman.
Researchers discovered specific mutations in the TACI gene that are associated with common variable immunodeficiency and IgA deficiency. These genetic defects impair the immune system's ability to fight infections, increasing the risk of recurrent illnesses and autoimmune diseases.
David M. Goldenberg, a pioneer in radiolabeled antibodies, has received the Society of Nuclear Medicine's 2005 Paul C. Aebersold Award. He has developed antibodies for various cancer types and therapies, making significant contributions to nuclear medicine.
Scientists at UCSD and Elan Pharmaceuticals have successfully vaccinated mice with a combination of human alpha-synuclein protein and adjuvant, reducing abnormal alpha-synuclein accumulation and promoting nerve cell survival.
A new study found that a combination of immunosuppressive therapies significantly reduces non-cellular and humoral rejection in heart transplant recipients. The TAC/MMF group showed the lowest incidence of any treated rejection and improved side effects compared to other groups.
Researchers develop customized antibodies that work together to target and destroy cancer cells. The therapy shows significant synergy, with a single combination of antibodies leading to more than three times greater effectiveness than a solo antibody in inhibiting HER2 signaling.
Researchers at the Weizmann Institute have developed a new technology that uses allicin to target and destroy cancer cells. By attaching the enzyme alliinase to an antibody already in clinical use, they can deliver a continuous supply of allicin to penetrate and kill cancer cells.
Researchers have discovered that natural protection against pneumococcal disease may not rely solely on antibodies. Long-lasting immunity to pneumococcus was found in mice exposed to live bacteria or a whole-cell vaccine, which stimulates CD4+ T-cells to provide protection at the earliest stage of infection.
Researchers developed plant-derived antibodies that protect against anthrax infection, providing immediate protection and a safe alternative to traditional vaccination methods. The plant-produced antibodies can be used before or after exposure and are stable for long periods, making them an attractive solution for stockpiling.
Researchers discovered that methamphetamine triggers an immune response by forming antibodies, leading to increased tolerance and binge behavior. This finding may lead to the development of specific antibodies as a clinical treatment for addiction.
A new study found that genetic amplification (NAAT) testing detects HIV more effectively than standard antibody testing in urban settings. The test identified four individuals with acute HIV infections who had previously tested negative, highlighting its potential to prevent transmission and improve early detection.
Researchers found that clearing Alzheimer's plaques leads to rapid recovery of normal brain structure in just three days. The study suggests that plaque-clearing treatments may slow or halt disease progression, and researchers plan to investigate the underlying mechanisms.
Researchers used PGD to select an RhD- embryo, resulting in a healthy baby girl. The technique aims to alleviate the risk of haemolytic disease of the fetus or newborn associated with RhD alloimmunization.
Researchers at Weill Cornell Medical College have developed a fast-acting anthrax vaccine that uses gene transfer technology to provide rapid immunity. The new vaccine works quickly, granting mice immunity within 12 to 18 hours of vaccination and may be used in combination with active vaccines for enhanced protection.
Researchers successfully silenced SDF-1's signal in mice with simulated retinopathy, effectively halting the growth of new blood vessels. The study could lead to a treatment option using routine injections of an antibody-blocking substance into a patient's eye.
Researchers have discovered a link between DNA movement and the formation of antibody genes in specialized blood cells. The study found that a specific type of transposable element is involved in both DNA recombination mechanisms, shedding light on their relationship and potential role in cancer development.
Researchers found that old T cells weaken the immune system in older mice, causing impaired B cell activation and antibody production. However, infusing young T cells into old mice restored B cell function, suggesting a key role for helper T cells in maintaining immune capacity with age.
The HMS vaccine, dl5-29, outperformed two established vaccines in animal models, demonstrating a stronger T cell response and broader antibody protection. The results suggest that dl5-29 is the most compelling new vaccine candidate for genital herpes, with potential to prevent infection and recurring disease.
A 12-center study found that an immune-modulating therapy, IVIG, reduces high antibody levels and improves transplantation rates in highly sensitized patients. The study showed a significant benefit of IVIG over placebo, with transplant rates more than double for the treatment group.
A new antibody treatment has shown promise in slowing or halting Crohn's disease by blocking the production of inflammatory proteins. The treatment was safe and effective in reducing symptoms in patients with active Crohn's disease.
Researchers found that injecting antibodies directly into the brain of mice slowed down plaque growth by up to two months without adverse side effects. This modified passive immunization method may offer a safer treatment option for Alzheimer's, providing a window for other treatments to prevent new plaque formation.
Researchers discovered a critical link in the molecular pathway that enables the immune system to target invaders with precision. The discovery may also provide new information on lymphoma, a type of leukemia where certain immune cells proliferate uncontrollably.
Researchers found that specific immunoglobins 'turn on' the IGF-1R, triggering inflammation and T lymphocyte activation. Blocking this interaction arrests molecular events leading to T cell activation, offering promise for a common therapeutic strategy for autoimmune diseases.
Scientists at Boston Children's Hospital have uncovered a crucial mechanism that enables B cells to produce unique, specialized antibodies by selectively targeting specific stretches of DNA. This discovery has significant implications for understanding the immune system and potentially preventing cancers like lymphomas.
Visilizumab shows promise in treating severe ulcerative colitis by blocking processes that lead to colon inflammation and damage. The new therapy offers an alternative to invasive surgery for patients with severe UC.
Researchers have developed a method that could vastly improve the ability of atomic force microscopes to 'see' the chemical composition of a sample, follow variations of the sample, and map its topographic structure. This new technique allows for molecular-scale imaging with increased sensitivity.
Researchers found that immune therapy against Alzheimer's disease not only removes the toxic amyloid plaque but also clears protein tangles, suggesting a broad assault on the disease. The treatment was shown to clear both hallmark lesions of AD by alleviating interference in the cell's protein garbage disposal system.
Researchers recommend performing oral food challenges on children with at least a 50-50 chance of passing, based on IgE antibody levels less than 2.0 kilounits per liter of blood. This guideline aims to reduce unnecessary avoidance of common allergenic foods and improve the accuracy of food allergy diagnosis.
A recent study found that B-cell targeted therapy significantly reduced arthritic symptoms in patients, with improvement lasting over a year and sometimes up to three years. The treatment has shown promise in breaking the cycle driving the disease, but further studies are needed to ensure its safety.
A small trial found that daclizumab add-on therapy reduced the severity and number of brain lesions in patients with relapsing-remitting or secondary progressive multiple sclerosis. The treatment, which blocks the interleukin-2 receptor on immune cells, showed unexpected clinical benefits in a small group of patients.
Researchers at VIB have developed nanobodies, tiny proteins that can target specific cancer cells. These nanobodies have shown promise in treating various diseases, including inflammatory and heart conditions.
Researchers have developed a second-generation targeted antibody, 806, which shows potent anti-tumor activity in animal models of human cancers that overexpress EGFR. The antibody binds specifically to activated EGFR on cancer cells, avoiding normal tissues.
A recent study has revealed a connection between FAP, a protein involved in tadpole tail resorption, and accelerated tumor growth in humans. Researchers found that producing high levels of FAP in the tumor microenvironment promotes cancer growth. The study also explores the potential use of antibodies to block FAP's action.
Scientists have found a possible way to rescue damaged neurons from death by targeting a specific protein. The research, published in the Proceedings of the National Academy of Sciences, suggests that a proNGF antibody can prevent the interaction between two cellular proteins that cause neuron damage.
A DNA vaccine has been shown to protect against anthrax, with the protective antigen (PA)-based vaccine proving more effective than the lethal factor (LF)-based vaccine. The study found that immunization with PA induces antibodies capable of neutralizing toxin and conferring protection.
Roald Hoffmann highlights the overlooked scientific achievements of his wife, Marie-Anne Pierrette Paulze Lavoisier, and her husband Antoine Lavoisier. The collection at Cornell University provides insight into their lives and work.
A new study suggests that maternal circulating cells can migrate to the heart of infants, potentially causing a damaging immune response. The research, led by Dr. Anne Stevens, found that these cells were present at higher levels in the hearts of babies with neonatal lupus syndrome, which can cause severe heart damage.
Researchers detected 'atheronals', toxic compounds triggered by ozone in atherosclerotic plaques, suggesting a potential diagnostic marker for late-stage arterial inflammation. Ozone's role in human biology and its implications on diseases like lupus, multiple sclerosis, and rheumatoid arthritis are also explored.
A study found that four paleontologists developed acute illness after returning from expeditions in Mongolia, with antibodies detected in their blood. The risk of acquiring North Asian tick typhus is unknown during travel to endemic regions, and travelers should be suspected of having the disease even without a recognized tick bite.
Patients developing neutralizing antibodies had longer time to first relapse and increased yearly relapse rate compared to antibody-negative patients. The presence of antibodies did not affect overall disease outcome, but prompt consideration for alternative treatments may be necessary.
Researchers at UCSD investigate human dietary absorption of a cell-surface molecular sugar called N-glycolylneuraminic acid (Neu5Gc), found in red meat. The study reveals that people absorb and metabolize small amounts of Neu5Gc, triggering an immune response.
Hepatitis A vaccine boosters are unnecessary for healthy individuals, according to a meeting of experts; protective antibody amounts persist beyond 10 years after primary vaccination. Further investigations are needed for special patient groups.
Guideline suggests that early treatment with IVIg or plasma exchange can be beneficial for adults and children with severe, early Guillain-Barré syndrome. These treatments have been found to be equally effective in treating the condition.
The NIAID has launched a clinical trial to test an immunoglobulin product containing antibodies to West Nile virus (WNV) in treating severe WNV encephalitis. The study aims to assess the safety and efficacy of this treatment in preventing death or neurologic disability.
The Mayo Clinic team has successfully transplanted kidneys into 29 high-risk patients, achieving an 80% success rate. By filtering out antibodies from the patient's blood, they can create a less hostile environment for the donor kidney to adapt. This approach may change the fate of thousands of patients waiting for a transplant.
Researchers at Stanford Medicine developed a targeted DNA vaccine that can predict and treat autoimmune diseases like M.S. by analyzing antibody profiles. The vaccine uses tolerization to knock out harmful immune responses while leaving the rest of the system functional, offering new hope for personalized therapies.
Research suggests that cervical cancer vaccines may be less effective in women who are ovulating, due to fluctuations in antibody levels triggered by sex hormones. The study found higher antibody levels during the proliferative phase and lower levels around ovulation.
Scientists at Rice University have created a new test that can detect glycoprotein immunoglobulin G in whole blood with high sensitivity and speed. The innovation uses gold nanoshells to overcome challenges in existing immunoassays, enabling doctors to make quicker diagnoses without the need for time-consuming sample preparation.
A recent study published in the Canadian Medical Association Journal investigated the effects of a Chlorella-derived dietary supplement on immune function and influenza vaccination. The results showed no significant increase in antibody response to the flu vaccine overall, although some increase was seen in participants aged 50 to 55.
Researchers at USC successfully simulated the somatic hypermutation process in vitro, closely mirroring its natural occurrence. This breakthrough enables the development of an in vitro system that can mimic the body's immune response.
Scientists have determined the structure of the 2G12 antibody, which neutralizes HIV by binding to sugars on its surface. The antibody's unique structure could provide a template for designing an antigen that triggers the body to produce it, potentially leading to an HIV vaccine.
Jefferson scientists have developed a tobacco plant that produces human antibodies against rabies, addressing a global shortage of the treatment. The plant-based antibody is safer and less expensive than traditional methods, offering hope for millions affected by the deadly disease.
Scientists at the University of Toronto have made a breakthrough in understanding how to diagnose, treat, and potentially prevent infectious prion diseases like mad cow disease. By identifying specific amino acid sequences on abnormal prions, they were able to develop antibodies that can recognize and attack these rogue proteins.
The STAT program uses a combination of antibody tests and polymerase chain reaction (PCR) to detect acute HIV infections, which are often missed by routine testing. The approach has resulted in a 4% increase in new HIV diagnoses in North Carolina and has shown promise for reducing transmission and saving lives.
A study published in Science suggests that proteins normally pass into the kidneys and that kidney disease may result from an inability to draw them back out. Researchers identified at least two patients with kidney disease who lack one copy of CD2AP, a protein critical for kidney function.